A Non-randomized, Non-Interventional, Prospective, Multicenter, Post Marketing Surveillance Study to Assess the Antibacterial Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative (Preoperative and Postoperative) Sterilization in Patients Undergoing Ophthalmic Surgery
Latest Information Update: 14 May 2024
At a glance
- Drugs Moxifloxacin (Primary)
- Indications Endophthalmitis; Postoperative infections
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 07 May 2024 Status changed from not yet recruiting to completed.
- 08 Jan 2024 Planned initiation date changed from 15 Nov 2023 to 28 Feb 2024.
- 30 Oct 2023 Planned End Date changed from 16 Feb 2024 to 15 May 2024.